Hepatic histological changes after 48 weeks adefovir dipivoxil treatment in patients with HBeAg- positive chronic hepatitis B

CHEN Yong,SI Chong-wen,ZHOU Xiao-jun

DOI: https://doi.org/10.3760/j.issn:1000-6680.2007.08.008

2007-01-01

Abstract:Objective To evaluate the hepatic histological changes of patients with HBeAg- positive chronic hepatitis B treated with domestic made adefovir dipivoxil(ADV).Methods It was a randomized,double blind,placebo-controlled,multieenter clinical trial.Patients with HBeAg-positive chronic hepatitis B were randomly assigned into group A(ADV was given orally at the dose of 10 mg once a day for 48 weeks)and group B(placebo was given for 12 weeks,followed by ADV at the dose of 10 mg once a day for 36 weeks)in a 1:1 ratio.Of 21 patients paired liver biopsy samples were taken before and after therapy,then were evaluated and scored according to Knodell's histological activity index(HAD and Ishak fibrosis evaluation.Results According the paired liver biopsy samples of 21 patients,median Knodell's HAI score and Ishak score were 11 and 3 points at baseline,5 and 2 points at the end of 48 weeks ADV treatment,respectively.There were significant reductions of HAI score and Ishak fibrosis scores after ADV treatment comparing with the baseline.Histological improvement rate after 48 weeks ADV treatment was 43%,while the fibrotic amelioration rate was 52%(P<0.05).Conclusions In the patients with HBeAg-positive chronic hepatitis B,48 weeks ADV treatment can significantly improve liver histological condition,including both necroinflamma- tion and fibrosis status.